Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hilecna Gel is a topical acne treatment containing 0.1% adapalene, developed and manufactured by Gujarat Pharma Lab. As a third-generation retinoid and a small molecule naphthoic acid derivative, adapalene selectively binds to nuclear retinoic acid receptors (RARs), specifically the RAR-β and RAR-γ subtypes. This binding modulates gene expression to normalize follicular epithelial differentiation, thereby reducing the formation of microcomedones and preventing the development of acne lesions. Additionally, Hilecna Gel exhibits anti-inflammatory properties by inhibiting the oxidative metabolism of arachidonic acid and the chemotactic response of inflammatory cells. It is indicated for the topical treatment of acne vulgaris and is formulated as a gel for localized application.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hilecna Gel.